semaglutide
-
【Product for Licensing】ALK7-targeting siRNA Therapeutics for fat reduction without muscle loss
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
Musk’s Hobby Also Sparks a Boom for WuXi AppTec!
For more reports, please follow DrugTimes
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
What is the Current Landscape of Obesity Drug Development in China?
These presentations indicate that the era of domestically developed GLP-1 drugs for weight loss in China is on the horizon, with significant implications for the future of obesity treatment
